NPCE News and Press, Neuropace Inc. From 10/17/23

- Upgraded nSight Platform Improves Clinicians’ Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming’ Enables Complete Programming Set Transfer Directly to RNS Tablet - - FDA Approval of Smaller, Portable and Simpler Tablet Remo...

MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2023 after market close on...

MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023 Cantor Fitzgerald ...

2023-09-05 05:22:56 ET Summary NeuroPace aims to improve the lives of epilepsy patients with its remote monitoring system. The company's RNS system offers personalized and real-time treatments for epilepsy patients. NeuroPace has seen improved commercial traction and increased...

2023-08-31 10:00:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...

- Wells Fargo 2023 Healthcare Conference - - Morgan Stanley 21 st Annual Global Healthcare Conference - - Lake Street Capital Markets 7 th Annual Best Ideas Growth Conference - MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (...

2023-08-24 10:00:34 ET Gainers: CollPlant Biotechnologies ( CLGN ) +11% NeuBase Therapeutics ( NBSE ) +7% NeuroPace ( NPCE ) +7% Bionomics ( BNOX ) +6% Enhabit ( EHAB ) +16% Losers: NanoVibronix ( NAOV ) -15% ...

2023-08-11 10:17:08 ET NeuroPace, Inc. (NPCE) Q2 2023 Earnings Conference Call August 08, 2023 04:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial ...

2023-08-08 16:21:29 ET NeuroPace press release ( NASDAQ: NPCE ): Q2 GAAP EPS of -$0.36 beats by $0.11 . Revenue of $16.5M (+61.8% Y/Y) beats by $3.87M . Full-year revenue guidance increased to $59-$61 million, up from $52-54 million. Cash burn reduced to $4...

Second quarter 2023 revenue of $16.5 million increased 62% year-over-year Full-year revenue guidance increased to $59-$61 million, up from $52-54 million Cash burn reduced to $4 million in the second quarter of 2023, relative to $9.8 million in the first quarter of 2023 MO...